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C A N C E R
RING1B recruits EWSR1-FLI1 and cooperates 
in the remodeling of chromatin necessary for Ewing 
sarcoma tumorigenesis
Sara Sánchez-Molina1*, Elisabet Figuerola-Bou1, Enrique Blanco2,3, María Sánchez-Jiménez1, 
Pablo Táboas1, Soledad Gómez1, Cecilia Ballaré2,3, Daniel J. García-Domínguez4,  
Estela Prada1, Lourdes Hontecillas-Prieto4, Ángel M. Carcaboso1, Óscar M. Tirado5, 
Inmaculada Hernández-Muñoz1,6, Enrique de Álava4,7, Cinzia Lavarino1,8,  
Luciano Di Croce2,3,9*†, Jaume Mora1,8*†
Ewing sarcoma (EwS) is an aggressive tumor that affects adolescents and young adults. EwS is defined by a 
chromosomal translocation, EWSR1-FLI1 being the most common, that causes genome reprogramming 
through remodeling of enhancers. Here, we describe an unexpected function of RING1B, which is highly 
expressed in EwS. While retaining its repressive activity at Polycomb developmental regulated genes, RING1B 
colocalizes with EWSR1-FLI1 at active enhancers. We demonstrate that RING1B is necessary for the expression 
of key EWSR1-FLI1 targets by facilitating oncogene recruitment to their enhancers. Knockdown of RING1B 
impairs growth of tumor xenografts and expression of genes regulated by EWSR1-FLI1 bound enhancers. 
Pharmacological inhibition of AURKB with AZD1152 increases H2Aub levels causing down-regulation of 
RING1B/EWSR1-FLI1 common targets. Our findings demonstrate that RING1B is a critical modulator of EWSR1-
FLI1–induced chromatin remodeling, and its inhibition is a potential therapeutic strategy for the treatment of 
these tumors.
INTRODUCTION
Ewing sarcoma (EwS) is an aggressive, poorly differentiated, human 
tumor characterized by a chromosomal translocation involving a mem-
ber of the FET family of genes (FUS, EWSR1 and TAF15) and a member 
of the ETS family of transcription factors, with the EWSR1-FLI1 gene 
fusion the most common one (1). EwS genomes present low mutation 
rates with FET-ETS rearrangements as the dominant genetic aberration 
in the majority of tumors (2). Notably, the cell of origin of EwS is still a 
controversial field, although human mesenchymal stem cells (hMSCs) 
and human neural crest stem cells are the most accepted (3–5).
The EWSR1-FLI1 fusion protein, which contains the transcrip-
tional activation and RNA binding domains of EWSR1 and the DNA 
binding domain of FLI1, is the main driver of tumorigenesis 
(3, 6). The resulting fusion oncoprotein has the ability to act as 
an aberrant transcription factor, leading to gene activation and re-
pression for a well-described set of genes (3,  7). A decade ago, 
EWSR1-FLI1 was found to bind preferentially to DNA sites contain-
ing GGAA microsatellite repeats (8, 9). Recent studies have reported 
that binding of EWSR1-FLI1 multimers to GGAA repeats acts as a 
pioneer factor and induces the formation of de novo active enhancers 
by recruiting the acetyl transferases CBP/p300, E2F3, and the BRG1/
BRM-associated factor chromatin remodeling complex (10–12). On 
the other hand, it was hypothesized that monomeric EWSR1-FLI1 
inhibits transcription at enhancers by displacing endogenous ETS 
transcription factors from GGAA motifs (10). Therefore, the mech-
anisms by which EWSR1-FLI1 acts as either a gene activator or re-
pressor depend on both DNA sequence and cofactors.
Several proteins from the Polycomb group (PcG) have previously 
been implicated in EwS tumorigenesis. PcG was first described in 
Drosophila melanogaster as a key regulator of Hox genes expression. 
PcG proteins not only prevent differentiation by repressing lineage- 
specific genes but also mark bivalent chromatin regions for sub-
sequent activation. EZH2 (the enzymatic subunit of PRC2) methylates 
histone H3 at lysine 27 (H3K27me3), while RING1B (the enzymatic 
subunit of PRC1) ubiquitinates H2A at lysine 119 (H2Aub), both 
considered repressive histone marks (13).
The canonical PRC1 complex (defined by the presence of four sub-
units, comprising one variant each of PCGF, PHC, CBX, and RING1) 
has mostly been associated with maintaining gene repression. How-
ever, increasing evidence indicates that PRC1 complexes containing 
RING1B have the potential for transcription activation, via their 
catalytic-independent association with UTX, an H3K27me3 demethyl-
ase, and p300 acetyltransferase (14, 15). With respect to EwS, it was 
recently shown that EZH2 blocks endothelial and neuroectodermal 
differentiation (16), BMI1 promotes tumorigenicity (17), and RING1B 
represses the nuclear factor B pathway (18). The molecular mech-
anisms behind the contribution of PcG to EwS have not been ad-
dressed. Notably, the GGAA repeats are significantly decorated with 
H3K27me3 in H1 human embryonic cell lines and human umbilical 
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vein endothelial cells (HUVECs) (19). This is in stark contrast 
with the lack of H3K27me3 mark at EWSR1-FLI1 binding sites in 
EwS cells (10, 11), thus suggesting a different role of PcG in EwS. 
Last, comparison between malignant and nonmalignant tissues 
revealed a misregulation of PcG target genes in EwS (20). Together, 
these findings suggest a potential role of the PcG during the early 
steps of EwS pathogenesis. Here, we report that RING1B and 
EWSR1-FLI1 interact and colocalize at the same genomic loci. 
Notably, we find that RING1B is present at promoters and en-
hancers of actively transcribed EWSR1-FLI1 target genes. Fur-
thermore, we demonstrate that modulation of RING1B interferes 
with EWSR1-FLI1 recruitment and with the expression of EWSR1-
FLI1 targets, thus unveiling an interdependent cooperation between 
both proteins.
RESULTS
EWSR1-FLI1 targets PcG-repressed regions in hMSC
Human pediatric MSCs (hpMSCs) have been proposed as a plausible 
cell of origin for EwS (21). Nevertheless primary human endothelial 
HUVECs share high similarity in gene expression profiles with EwS cells 
(22). Thus, to investigate the potential contribution of epigenetic alteration 
in the initiation of EwS, we analyzed the role of epigenetic marks in 
these models and compared to established EwS cell lines. We first 
analyzed the levels of H3K27me3 and H3K4me3 in the human 
EwS-derived cell line A673 at several bona fide direct targets of 
EWSR1-FLI1 (table S1) by chromatin immunoprecipitation followed 
by quantitative polymerase chain reaction (ChIP-qPCR). Promoter 
of genes that are transcriptionally activated by EWSR1-FLI1, such 
as FCGRT, NR0B1, CACNB2, EZH2, IGF1, NKX2-2, and HOXD11, 
was enriched for the H3K4me3 mark, and lacked the H3K27me3 
mark, in agreement with previous data (8, 20, 23, 24) (fig. S1A). On 
the other hand, transcriptionally repressed genes, such as KCNA5 
(25), were enriched for H3K27me3. We next compared the levels of 
H3K27me3 and H3K4me3 at the same loci in HUVECs and in 
hpMSCs. In an apparently reversed situation to the A673 EwS cell 
line, analysis of those promoters presented strong enrichment for 
H3K27me3 but not for H3K4me3 (fig. S1B). Accordingly, infection 
of HUVECs with the EWSR1-FLI1 oncogene (Fig. 1A) not only 
led to the activation of these targets (FCGRT, NR0B1, CACNB2, 
EZH2, IGF1, NKX2-2, and HOXD11) (Fig. 1B) but also decreased 
the levels of H3K27me3 (Fig. 1C). This demonstrates that, although 
H3K27me3 is not present at oncogene binding regions in EwS cell 
lines such as A673, these regions are repressed by PcG before onco-
gene expression.
To explore the chromatin and transcriptional states of EWSR1-
FLI1 binding sites (10), we measured the frequency of each chromatin 
state at these regions (26) and compared to the corresponding value 
obtained for the whole genome in several cell lines [HUVECs, H1, 
and H9 human embryonic cells, H1-derived MSCs, bone marrow 
(BM)–derived MSCs, and adipose-derived MSCs]. This analysis 
indicated that EWSR1-FLI1 binding sites are overrepresented in chromatin 
states associated with zinc finger genes and repeats (ZNF/repeats) and 
active promoters (Fig. 1D and table S1). In cells with MSC origin (such 
as H1, adipose, and BM-derived cell lines), EWSR1-FLI1 binding sites 
are overrepresented in PcG weak repressed state, which represents 
flanking regions of H3K27me3 peaks summit (Fig. 1D and fig. S1, 
C and D). Similar results were obtained when we grouped chroma-
tin states of similar categories (Fig. 1E). This suggests that EWSR1-
FLI1 occupies flanking regions of H3K27me3 summit peaks in hMSC, 
which are considered to be the potential cell of origin for EwS.
Data from our group have revealed that the PRC1 subunit 
RING1B, is highly overexpressed in EwS primary tumors (18). 
We thus assessed whether RING1B modulates the growth rate of 
EwS cells as has been reported for other PcG subunits, such as 
EZH2 and BMI1 (16, 17). RING1B depletion caused a reduction 
in cell viability in the A673, SK-ES1, and, with a lesser extent, in 
A4573 EwS cell lines but not in the control cell line 293T (Fig. 1F 
and fig. S1E), suggesting that RING1B represents an epigenetic 
vulnerability for EwS cells.
RING1B colocalizes genome-wide with EWSR1-FLI1 at  
active enhancers
Chan et al. (27) recently proposed that RING1B might play a role in 
modulating enhancer activity. Together with its role in promoter 
regulation, EWSR1-FLI1 has been recently reported to generate de 
novo enhancers (10). This led us to postulate whether EWSR1-FLI1 
and RING1B might cooperate during EwS tumorigenesis. We first 
aimed to define the genome-wide localization of RING1B and its 
repressive histone mark H2Aub in the A673 cell line by chromatin 
immunoprecipitation sequencing (ChIP-seq). In two independent 
experiments, we identified 2573 and 3945 peaks of RING1B, and 
26424 and 10269 peaks of H2Aub. Using differential binding anal-
ysis (DiffBind), which allows for the identification of statistically 
common peaks (28), we found 2459 RING1B and 5392 H2Aub sig-
nificant peaks between duplicates (P < 0.05, fig. S2A), corresponding 
to 1264 target genes and 3013 target genes, respectively (table S2). 
Genomic distribution of peaks showed that RING1B is more abun-
dant in intergenic regions, whereas H2Aub is mainly located in pro-
moters (Fig. 2A). Moreover, 38% of RING1B peaks were found at 
intergenic regions with respect to 21.5% of H2Aub peaks, and 29.2% 
of RING1B peaks were in promoters with respect to 40.5% of H2Aub 
peaks, further supporting the potential role of RING1B at enhancers. 
We then categorized peaks for RING1B, H2Aub, and EWSR1-FLI1 
in active or poised enhancers, and in active or poised promoters, 
based on H3K27me3, H3K4me3, H3K27ac, and H3K4me1 (29). To 
complement the above data, we performed a ChIP-seq analysis using 
a different antibody directed against FLI1 (fig. S2B and table S2). 
We found that an important fraction of RING1B peaks (35%) and 
EWSR1-FLI1 (46%) are located at transcriptionally active enhancers 
and promoters of A673 cells (Fig. 2B, left). On the other hand, as 
expected, 35% of RING1B peaks and 37% of H2Aub peaks showed 
a preference for transcriptionally repressed regulatory regions (Fig. 2B, 
left). We then intersected the list of genes associated to RING1B and 
H2Aub peaks with published data of EWSR1-FLI1 target genes 
in A673 cells, producing a common set of 162 genes (fig. S2C and 
table S3). Comparing this set with 386 genes containing only RING1B 
and H2Aub or the group of 324 EWSR1-FLI1/RING1B genes without 
H2Aub confirmed that the presence of EWSR1-FLI1 correlated with 
higher level of transcription (P < 10−16; fig. S2D, left). Functional 
analysis of the common gene set of 324 EWSR1-FLI1/RING1B 
genes (table S3) returned Gene Ontology (GO) categories related 
to chondrocyte and neuronal differentiation (fig. S2D, right). 
EWSR1-FLI1/RING1B/H2Aub genes were also enriched in neuro-
nal differentiation category, while the RING1B/H2Aub genes were 
related to general transcription. These data suggest that RING1B is 
a positive regulator of a specific set of genes implicated in EwS and 
that this activity is independent of its canonical repressive mark.
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Fig. 1. EWSR1-FLI1 targets PcG-repressed regions in hMSC. (A) Western blot showing ectopic expression of EWSR1-FLI1 upon infection of HUVECs with an empty pLIV 
vector or EWSR1-FLI1pLIV. (B) RT-qPCR determination of relative mRNA expression of EWSR1-FLI1 target genes upon infection of HUVECs with an empty pLIV vector or 
EWSR1-FLI1pLIV. Values are normalized to TBP. (C) H3K27me3 ChIP-qPCR at EWSR1-FLI1 target gene promoters in HUVECs infected with an empty pLIV vector or 
EWSR1-FLI1pLIV. The values of the Y axis represent the enrichment ratio of immunoprecipitated samples relative to input with subtracted immunoglobulin G (IgG). 
(D) Bar plots of chromatin state relative frequencies in the whole genome [background (BG)] and in published EWSR1-FLI1 binding sites (FLI1) for three selected cell lines. 
Genome segmentations were extracted from the Epigenome Roadmap Consortium. (E) Heatmap with percentages of each chromatin state in the whole genome (BG) as 
compared to the frequency within published EWSR1-FLI1 binding regions for indicated cell lines by grouping in 8 similar chromatin states the initial classification contain-
ing 15 (quiescent segments were excluded). Bold format indicates enrichments greater than 10%. Enrichment scores were calculated as the difference between the value 
in EWSR1-FLI1 and the value at the whole genome, normalized by the value at the whole genome. (F) Cell proliferation expressed as cell number in 293T, A673, SK-ES1, 
and A4573 cells transiently transfected with small interfering RNA (siRNA) against a control (siCTRL) or two different RING1B sequences (siRING1B#1 and #2). Error bars in 
(B), (C), and (F) indicate SD of three biological independent experiments. Statistical significance in (D) and (F) is as follows: ***P < 0.001 and *P < 0.05.
Sánchez-Molina et al., Sci. Adv. 2020; 6 : eaba3058     23 October 2020
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Fig. 2. RING1B colocalizes genome-wide with EWSR1-FLI1 at active enhancers. (A) Pie chart showing genomic distribution of RING1B and H2Aub peaks relative to 
functional categories including promoter (±2.5 kb from TSS), gene body (intragenic region not overlapping with promoter), and intergenic (rest of the genome). (B) Boxplot 
depicting percentage of regulatory elements (active/bivalent enhancers and promoters) in each described group. (C) Venn diagram depicting the overlap between RING1B 
and EWSR1-FLI1 in A673 cells at the peak level. (D) Aggregated plot showing the average ChIP-seq signal of RING1B and EWSR1-FLI1 at EWSR1-FLI1 binding sites. (E) Aggregated 
plots showing the average ChIP-seq signal of H3K27ac, H2Aub, and H3K27me3 in the three sets of RING1B and EWSR1-FLI1 peaks. (F) Heatmap showing RING1B, EWSR1-FLI1, 
H3K27ac, H2Aub, and H3K27me3 ChIP-seq signals segregating in the three sets of RING1B and EWSR1-FLI1 peaks. Top MEME motif for every group is shown. (G) University of 
California Santa Cruz (UCSC) genome browser ChIP-seq signal tracks for RING1B, EWSR1-FLI1, H2Aub, H3K27ac, H3K4me3, and H3K27me3 at NKX2-2, CCND1, VRK1, and CAV1 gene 
promoters and intergenic enhancer regions. Gray boxes represent EWSR1-FLI1 and RING1B colocalization and ES super-enhancers (SEnh; as shown at VRK1 and CAV1/2).
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To fully understand the association of RING1B with transcrip-
tional activation in EwS, we intersected EWSR1-FLI1 peaks with those 
of RING1B and obtained 955 common regions (Fig. 2C). Notably, 
intersection between H2Aub and RING1B peaks returned only 589 
common peaks. Among the 955 overlapping EWSR1-FLI1/RING1B 
peaks, we inspected for genes containing an enhancer within 100 kb 
and obtained 1276 genes, of which 235 (18%) were reported to be 
regulated by EwS super-enhancers (table S4) (11). The common 
targets of RING1B and EWSR1-FLI1 sites were found within active 
enhancers, while the majority of RING1B peaks not overlapping with 
EWSR1-FLI1 were located in transcriptionally repressed regulatory 
elements (Fig. 2B, right). The distribution of RING1B peaks was 
centered on EWSR1-FLI1 binding sites (Fig. 2D), suggesting that 
their binding occurs at the same loci. We next assessed the distribu-
tion of H3K27ac, H2Aub, and H3K27me3 in genomic regions occu-
pied by EWSR1-FLI1, RING1B, or shared (Fig. 2E). Common peaks 
were decorated with H3K27ac, lacking H2Aub (Fig. 2, E and F), and 
presented narrow RING1B peaks located in intergenic or intronic 
regions (fig. S2E, right). These data suggest that common sites likely 
represent enhancers. Known EWSR1-FLI1 target genes such as NKX2-2, 
CCND1, VRK1, or CAV1 presented an intergenic peak of RING1B, 
which overlaps with defined super-enhancers in the case of VRK1 
and CAV1 (Fig. 2G). Intronic enhancers such as JARID2 or MYOM2 
(fig. S2G) constitute the majority of the 162 common RING1B, 
EWSR1-FLI1, and H2Aub genes (53% of sites, fig. S2C). On the 
other hand, RING1B-specific peaks were associated with H3K27me3 
and H2Aub (Fig. 2, E and F) and presented a broader distribution 
[e.g., HNF1B and TAL1 (fig. S2H)] mainly located within promoter 
or gene body regions (fig. S2E, left). The bivalent marks H3K4me3 
and H3K27me3 decorated 63% of the 932 downstream genes asso-
ciated to RING1B-specific peaks (P < 10−300, table S4) (29). RING1B–
transcription start sites (TSS) do not overlap with EWSR1-FLI1 and 
are decorated with H2K27me3 and H2Aub, while RING1B-distal 
sites overlap with EWSR1-FLI1 and with H3K27ac (fig. S2F).
Last, de novo motif analysis revealed that EWSR1-FLI1–specific 
sites contained predominantly (P < 10−282) one single occurrence of 
the canonical ETS motif GGAA (Fig. 2F). When EWSR1-FLI1 was 
associated with RING1B, we observed a significant enrichment for 
multimeric GGAA repeats (P < 10−1072) (10). Furthermore, RING1B- 
sepecific sites were enriched for CG sequence, as previously reported 
(P < 10−176) (30). Together, we identified two major types of RING1B 
peaks in EwS: a prominent group with narrow peaks that colocalizes 
with EWSR1-FLI1 at enhancers of actively transcribed genes and a 
second group with broader peaks located at promoters, where RING1B 
is associated with H2Aub.
RING1B regulates the expression of EWSR1-FLI1 activated 
and repressed targets
To further characterize RING1B binding regions (table S4), we ana-
lyzed several EWSR1-FLI1 active promoters (CAV1, FCGRT, NR0B1, 
CACNB2, FEZF1, and KIAA1797) and enhancers (CCND1, IGF1, 
CAV2, JARID2, VRK1, and NKX2-2) by ChIP-qPCR. Both groups 
showed enrichment for RING1B, with stronger signals at enhancers 
(Fig. 3A). Known repressed targets of the oncogene (e.g., IGFBP3, 
TGFBR2, and LOX) also showed binding of RING1B. At these re-
pressed promoters, RING1B was accompanied by its canonical re-
pressive mark H2Aub (fig. S3A). We also validated the occupancy 
of RING1B in EWSR1-FLI1–activated promoters (CAV1, FCGRT, 
NR0B1, and FEZF1) and enhancers (CCND1, CAV2, JARID2, and 
VRK1) in SK-ES1 cells (fig. S3B). Similar to A673 cells, H2Aub cor-
related with RING1B at promoters of repressed genes (IGFBP3, 
TGFBR2, and LOX) (fig. S3C). Last, we observed that the PRC1 and 
PRC2 subunits, BMI1 and EZH2, respectively, were present at re-
pressed promoters but not in active enhancers (fig. S3, D and E), as 
well as in promoters with broad peaks of RING1B concomitant with 
H3K27me3 and H2Aub but no EWSR1-FLI1 (e.g., TAL1, IGF1R, 
and HNF1B) (fig. S3F). Furthermore, genome-wide analysis demon-
strated that BMI1 and CBX7 (31) subunits of the PRC1 canonical 
complex colocalize with RING1B only at repressed regions (TAL1) 
as shown in Fig. 3B, while no detectable peaks are present at active 
enhancers where EWSR1-FLI1 is present (VRK1). Thus, while 
RING1B decorates EWSR1-FLI1–activated promoters and enhancers, 
it also maintains its canonical role at several oncogene repressed 
regions, as well as in a subgroup of genes with no EWSR1-FLI1.
To understand whether RING1B behaves as a canonical repressor 
and/or activator in EwS, we analyzed the expression changes after 
knocking down RING1B using two different sets of short hairpin 
RNA (shRNA, seq#1 and seq#2; fig. S4A). The data obtained showed 
that 71.94 and 63.85% of genes were down-regulated in the A673 and 
SK-ES1 cell lines, respectively (FC < -1.5, Fig. 3C). This confirms our 
finding that RING1B acts predominantly as an activator, despite its 
presence at several EWSR1-FLI1–repressed targets. Furthermore, 
H2Aub levels remained unchanged after RING1B knockdown 
(Fig. 3D), while RING1A knockdown produces a notable decrease 
in H2Aub levels (fig. S4B). These data suggest that RING1B main 
function in EwS is uncoupled from its ubiquitin ligase activity toward 
H2A and that RING1A is the main histone H2A mono-ubiquitin 
ligase. To further elucidate to what extent RING1B cooperates with 
EWSR1-FLI1 in transcription regulation, we intersected differentially 
expressed genes in RING1B knockdown cells (absolute FC > 1.25) with 
those affected by EWSR1-FLI1 knockdown (absolute FC > 1.5) (10), 
obtaining an overlap of 1078 genes. After segregating these data into 
down- and up-regulated genes, we found that RING1B and EWSR1-
FLI1–activated 229 genes and repressed 162 genes (Fig. 3E and table S5). 
Among the 229 activated genes, we found several developmental genes, 
including SOX2, SIX3, LYAR, and KIT. GO analysis showed regu-
lation of the potassium channel and mechanisms that control actin 
monomers and filaments as the main categories (fig. S4C), in agree-
ment with previous publications (25, 32). Among the activated 
genes, SOX2 and KIT harbored RING1B and EWSR1-FLI1 peaks 
in intergenic and intronic enhancer regions, respectively (fig. S4E). 
TGFBR2, a gene repressed by both EWSR1-FLI1 and RING1B, also 
contained an intronic enhancer where both proteins colocalized. 
Notably, the expression of known targets of EWSR1-FLI1, such as 
NKX2-2 or IGF1 (fig. S4D), was just below our logFC cutoff value. 
Nonetheless, we confirmed by reverse transcription (RT)–qPCR the 
changes in expression levels of selected repressed and activated genes 
cobound by EWSR1-FLI1 and RING1B. We noticed that RING1B 
knockdown causes a significant reduction in the expression levels of 
those genes where both EWSR1-FLI1 and RING1B were co-occupying 
enhancer regions (Fig. 3, F and G). The expression of CAV1, NKX2-2, 
SOX2, IGF1, JARID2, and VRK1 was affected in stronger manner 
upon EWSR1-FLI1 knockdown, indicating that some cofactors could 
remain when RING1B is depleted (fig. S4F). The effect of RING1B 
knockdown was less pronounced when both proteins were enriched 
at promoter regions of active genes (fig. S4, G and H, left). As expected, 
at those genes where EWSR1-FLI1 acts as a repressor, RING1B 
knockdown induces a promoter reactivation (fig. S4, G and H, right). 
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Fig. 3. RING1B regulates the expression of EWSR1-FLI1–activated and EWSR1-FLI1–repressed targets. (A) RING1B ChIP-qPCR of EWSR1-FLI1 bound active promot-
ers, repressed promoters, and active enhancers. Control regions indicate the absence of RING1B and EWSR1-FLI1 binding at these sites. The values of the Y axis represent 
the enrichment ratio of immunoprecipitated samples relative to input. (B) UCSC genome browser ChIP-seq signal tracks for EWSR1-FLI1, RING1B, CBX7, BMI1, H2Aub, and 
H3K27me3 at TAL1 promoter and VRK1 enhancer. (C) Histogram depicting percentages of activated and repressed genes in A673 and SK-ES1 cells with stable RING1B 
knockdown seq#2 (shRING1B#2) versus control seq#2 (shCTRL#2), with P < 0.05 and an absolute fold change (FC) > 1.25 or 1.5. (D) Western blot showing RING1B, RING1A, 
H2Aub, and H3K27me3 in A673 and SK-ES1 cells with either shCTRL#2 or shRING1B#2. Lamin B and histone H4 are used as loading controls. (E) Venn diagram showing 
intersection between differentially activated or repressed genes for EWSR1-FLI1 and RING1B in A673 cells; P < 0.05. (F) RT-qPCR determination of mRNA expression of 
EWSR1-FLI1 target genes with active enhancers in shCTRL and shRING1B A673 cells (#1 and #2). Values are normalized to GAPDH. (G) Same analysis as in (F) for SK-ES1 
cells. Error bars in (A), (F), and (G) indicate SD of four independent biological experiments and ***P < 0.001, **P < 0.01, and *P < 0.05.
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Overall, these data indicate that RING1B and EWSR1-FLI1 cooperate 
in gene activation, at both the promoter and enhancer levels, while 
RING1B retains its canonical role at those targets repressed by the 
oncogene. Since a large number of EWSR1-FLI1 and RING1B co-
targets were not altered by RING1B knockdown, we postulate com-
pensatory mechanism(s) or additional cofactors involved in their 
regulation.
RING1B interacts with EWSR1-FLI1 and affects its 
recruitment to chromatin
Wild-type EWSR1 interacts with RING1B in the VCaP prostate 
cancer cell line (33). We also confirmed this interaction in SK-ES1 
cells (Fig. 4A). Since RING1B and EWSR1-FLI1 are enriched at 
transcriptionally active regions, we next aimed to investigate whether 
both proteins interact. Coimmunoprecipitation experiments in HeLa 
cells where EWSR1-FLI13xFlag was overexpressed (34) confirmed 
that indeed oncogene interacts with RING1B (Fig. 4, B and C). 
Analysis of published mass spectrometry data demonstrated that 
several SWI/SNF subunits interact with RING1B (33), further sup-
porting an active role of RING1B in EwS gene regulation. Together, 
our results indicate that EWSR1-FLI1 and RING1B not only colocalize 
at the same genomic regions but also physically interact, mainly 
through the EWSR1 component of the fusion protein.
Next, we analyzed whether RING1B depletion affects the EWSR1-
FLI1 recruitment to chromatin. As expected, after knockdown, we 
observed a notable reduction of RING1B in the chromatin bound 
fraction (Fig. 4D). EWSR1-FLI1 was also evicted from chromatin 
bound and enriched in the soluble chromatin fraction (Fig. 4D). We 
then monitored the occupancy of EWSR1-FLI1, RING1B, and 
H3K27ac at several enhancers (e.g., SOX2, NKX2-2, and IGF1). 
The data in Fig. 4E showed that upon RING1B knockdown, enrich-
ments at those enhancers decreased to control values [immuno-
globulin G (IgG) or ENC1 region]. To assess the decrease of 
EWSR1-FLI1 recruitment genome-wide, we performed ChIP-seq 
analysis of RING1B and FLI1 in shCTRL and shRING1B A673 cells. 
The analysis indicated that upon RING1B depletion, EWSR1-FLI1 
binding to chromatin was reduced (Fig. 4, F and G). In sum, we 
conclude that in EwS, RING1B exerts its main role as activator by 
promoting recruitment of EWSR1-FLI1 to enhancer regions.
RING1B knockdown decreases tumor growth in vivo
RING1B stimulates tumor growth and metastasis in melanoma, 
leukemia, and breast cancers (14, 27). We observed a reduction in 
colony number when RING1B is depleted in the SK-ES1 cell line 
(fig. S5A). To gain functional insight into the cancer pathways po-
tentially modulated by RING1B, we performed gene set enrichment 
analysis (GSEA) by comparing SK-ES1 shCTRL versus shRING1B 
cells. The top 10 most significant pathways included interferon-, 
epithelial-to-mesenchymal transition, hedgehog signaling, and 
angiogenesis, with a 0.25 Q value cutoff (fig. S5B). In EwS, disrup-
tion of angiogenic pathways has been described (4, 22). Further 
inspection of angiogenic gene list revealed that key genes such 
as PDGFA, FGFR1, SLCO2A1, CXCL6, and S100A4 were down- 
regulated upon RING1B depletion (fig. S5C).
To assess the relevance of RING1B in vivo, we generated xeno-
grafts by injecting SK-ES1 shCTRL or shRING1B cells (seq#1 and 
seq#2) subcutaneously into athymic nude mice. Cells with reduced 
RING1B levels showed delayed engraftment and slower tumor growth 
(Fig. 5A). At 21 days after injection, tumors derived from shRING1B 
cells were significantly smaller than those from control cells (fig. S5D). 
Notably, the median survival increases from 26 days for shCTRL 
cells to 30 days for shRING1B seq#1 and from 20 to 27 days for 
shRING1B seq#2 (Fig. 5B). Immunohistochemical analyses of tumors 
confirmed reduced levels of RING1B, while the ES marker CD99 
remained essentially unchanged (Fig. 5C and fig. S5E). Furthermore, 
shCTRL tumors displayed higher proliferation rates than shRING1B, 
as shown by Ki-67 staining (Fig. 5C).
To better characterize xenograft derived tumors, we performed 
RNA sequencing (RNA-seq) of a cohort of tumors (six for each 
group, Fig. 5D). GSEA analysis confirmed the enrichment of angio-
genic genes in the shCTRL tumors (fig. S5, F and G). Since RING1B 
retains its repressive function at several promoters, we hypothesized 
that the delay in survival and in tumor growth upon RING1B 
knockdown could be related to up-regulation of tumor suppressor 
genes (TSG). GSEA applied to 983 genes from TSG database 
(https://bioinfo.uth.edu/TSGene), indicated that this gene list was 
enriched in shCTRL phenotype, suggesting that tumor growth and 
survival differences observed were not due to RING1B repression of 
TSG (fig. S5H). The NKX2-2, SOX2, and IGF1 genes are necessary 
for EwS tumor proliferation (21, 23, 35). In agreement, confirmed 
RING1B and EWSR1-FLI1 expression reduction (Fig. 5E) is associated 
to down-regulation of these genes in xenograft tumors (Fig. 5F, left), 
as we previously shown in EwS cells (Fig. 3, F and G). Furthermore, 
after RING1B knockdown, we also validated down-regulation of 
S100A4, SLCO2A1, and VEGFA, which are main activators of angio-
genic signaling pathways (Fig. 5F, right). All these data highlight the 
role of RING1B as an activator in EwS tumorigenesis.
EWSR1-FLI1/RING1B targets are regulated by  
AURKB inhibition
Several kinases (including AURKB, MEK1, and CK2) have been re-
ported to modulate the activating transcriptional function of RING1B 
(14, 15, 36). To investigate which pathway(s) regulates RING1B at 
active enhancers in EwS, we analyzed the expression levels of these 
three kinases in a publicly available database (4) comprising a cohort 
of 27 tumor samples and BM-MSCs. While MEK1 and CK2 were not 
expressed in primary tumors with respect to BM-MSCs (control), 11 
of 27 EwS tumors (40%) showed higher levels of AURKB compared 
to control (fig. S6A). EWSR1-FLI1 directly regulates the expression 
of AURKB (37), as also demonstrated by AURKB down-regulation 
in EwS cell lines upon oncogene knockdown (fig. S6A).
AZD1152 is a specific AURKB inhibitor, with a median inhibitory 
concentration (IC50) of 19 nM in EwS cell lines (38). Accordingly, we 
observed IC50 values of 5 and 6 nM in SK-ES1 and A4573 cells, respec-
tively; in contrast, the IC50 for A673 was 5 M, and AZD1152 had 
no effect on the control cell line 293T (fig. S6B). EwS cells that sur-
vived to the treatment showed an atypical phenotype, suggesting 
enhanced differentiation (fig. S6C). Furthermore, viability of EwS 
cell lines was not affected by the inhibition of RING1B E3 ubiquitin 
ligase activity with PRT4165 (fig. S6B). To further elucidate the 
effect of AZD1152 in EwS, cell death was analyzed by Annexin V 
staining. A 72-hour AZD1152 treatment of A673, SK-ES1, and 
A4573 cells led to an increase in the early and late apoptosis 
populations as compared to 293T cells (Fig.  6A). Analysis of 
cleaved PARP levels further demonstrated that AZD1152 stim-
ulated apoptotic pathways in EwS cell lines, with SK-ES1 being 
the most sensitive (Fig. 6B). It is worth noting that the levels of 
EWSR1-FLI1 were decreased after AZD1152 treatment in SK-ES1 
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Fig. 4. RING1B interacts with EWSR1-FLI1 and affects its recruitment to chromatin. (A) Western blot showing endogenous coimmunoprecipitation of RING1B with 
EWSR1 in the SK-ES1 cell line. (B) Western blot showing overexpression of EWSR1-FLI1-3xFlag and RING1B levels in HeLa stably transfected cells upon induction with 
indicated doxycycline concentrations for 24 hours. Calnexin is used as loading control. (C) Coimmunoprecipitation of RING1B with EWSR1-FLI1-3xFlag under induction 
conditions (0.5 g/ml). Inputs in (A) and (C) contain 10% of immunoprecipitated material and IgG is used as control. (D) Western blot showing RING1B and EWSR1-FLI1 in 
cytoplasm, soluble, and bound chromatin fractions in shCTRL#1 or shRING1B#1 SK-ES1 cells. Histone H4 is used as a control of bound chromatin, and GAPDH as a control 
of cytoplasmic fraction. Blot quantification of the same ordered samples is depicted below. (E) ChIP-qPCR analysis of FLI1, RING1B, and H3K27ac at EWSR1-FLI1–activated 
enhancers of NKX2-2, SOX2, or IGF1 genes in shCTRL#2 and shRING1B#2 A673 cells. ENC1 is used as negative control region. The values of the Y axis represent the enrich-
ment ratio of immunoprecipitated samples relative to input. Error bars indicate SD of three independent biological experiments. Statistical significance is as follows 
***P < 0.001, **P < 0.01, and *P < 0.05. (F) Aggregated plot and boxplot showing the average ChIP-seq signal of RING1B and FLI1 peaks at RING1B and EWSR1-FLI1 binding 
sites, respectively, in shCTRL#2 and shRING1B#2 A673 cells. (G) UCSC genome browser ChIP-seq signal tracks for EWSR1-FLI1 and RING1B in shCTRL#2 and shRING1B#2 
A673 cells at SOX2 and VRK1 enhancer regions.
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and A4573, yet RING1B levels were unaffected (Fig. 6B and fig. S6, 
D and E, right). To understand how AURKB modulates RING1B 
in EwS, we analyzed H2Aub levels after AZD1152 treatment. We 
observed increased levels of H2Aub repressive mark after AURKB 
inhibition, suggesting that this kinase indeed inhibits the ubiquitin 
ligase activity of RING1B in EwS (Fig. 6C). Furthermore, in SK-ES1 
and A4573 cells, the increase in ubiquitin ligase activity correlated 















2                 0                –2
shCTRL   shRING1B  
B
Z score 
Fig. 5. RING1B knockdown decreases tumor growth in vivo. (A) Tumor volume curve in xenografts established by subcutaneous injection of shCTRL and shRING1B#1 
(n = 9 and n = 10, respectively, above) or shRING1B#2 (n = 12 both groups, below) SK-ES1 cells in athymic nude mice. (B) Kaplan-Meier xenograft survival curves in shCTRL 
and shRING1B SK-ES1 cells (#1 and #2). (C) Immunohistochemistry staining of EWSR1-FLI1, CD99, and RING1B on sections of tumors excised from shCTRL#1 and 
shRING1B#1 SK-ES1 xenografts. Proliferation was analyzed by Ki67 immunohistochemistry; hematoxylin and eosin (H&E) was used as control. (D) Heatmap depicting fold 
changes in gene expression in six tumors excised from shCTRL#1 and shRING1B#1 SK-ES1 groups. (E) RT-qPCR levels of mRNA expression for RING1B and EWSR1-FLI1 in 
shCTRL#1 and shRING1B#1 SK-ES1–derived tumors; ***P < 0.001. (F) RT-qPCR levels of mRNA expression for genes regulated by EWSR1-FLI1/RING1B enhancers (left) and 
angiogenic genes (right) in shCTRL#1 and shRING1B#1 SK-ES1 derived tumors; *P < 0.05.
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Fig. 6. EWSR1-FLI1/RING1B targets are regulated by AURKB inhibition. (A) Annexin V staining of SK-ES1, A673, and A4573 cells after treatment with AZD1152 
(20 nM). 293T cells were used as a control cell line. (B) Western blot analysis of cleaved poly(ADP-ribose) polymerase (cPARP), EWSR1-FLI1, RING1B, and AURKB 
after treatment with 10 or 20 nM AZD1152, in the A673, SK-ES1, A4573, and 293T cell lines. Tubulin was used as loading control. (C) Western blot analysis of H2Aub 
and H3S10phospho (H3S10ph) in the A673, SK-ES1, and A4573 cell lines treated with 5 or 20 nM AZD1152. Histone H4 was used as loading control. (D) RT-qPCR 
determination of mRNA expression of target genes with RING1B/EWSR1-FLI bound enhancers in SK-ES1 and A4573 cells after treatment with 20 nM AZD1152. 
RPL27 was used for normalization. DMSO, dimethyl sulfoxide. (E) AURKB ChIP-qPCR at CAV2 and SOX2 EWSR1-FLI1/RING1B enhancers (above) and control regions 
(below). The values of the Y axis represent the enrichment ratio of immunoprecipitated samples relative to input. Error bars in (D) and (E) indicate SD of three 
independent biological experiments. (F) Schematic representation illustrating the EWSR1-FLI1 recruitment by RING1B to repressed regions containing GGAA 
repeats. Once EWSR1-FLI1 has been recruited, additional cooperating factors such as AURKB might inhibit RING1B ubiquitin ligase activity, which, in turn, is able 
to participate in transcription activation.
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RING1B, with more pronounced effect on those genes where both 
proteins colocalize at the enhancer region (Fig. 6D and fig. S6, D 
and E, left). For the A673 cell line, higher doses were required to 
reach oncogene target deregulation, as expected. Next, we reasoned 
that AURKB should be present at those regions where it inhibits 
RING1B activity. Using ChIP-qPCR, we demonstrated that AURKB 
is enriched in active enhancers (CAV2, driving CAV1 expression, 
and SOX2; Fig. 6E) and promoters (NR0B1; fig. S6F). Furthermore, 
EWSR1-FLI1 down-regulation could be explained by the presence 
of RING1B at the EWSR1 promoter, which indirectly decreases 
upon AZD1152 incubation (fig. S6G). Although part of AZD1152 
cytotoxicity might be related to reduction of EWSR1-FLI1 availability, 
the data presented suggest that RING1B regulation of oncogene targets 
is susceptible to AURKB inhibition. The translational value of this 
potential targetable vulnerability is the matter of ongoing work.
DISCUSSION
RING1B in active enhancers
Here, we investigated the genome-wide occupancy of RING1B in 
EwS. In agreement with previous data, we identified a set of regions 
bound by RING1B where it exerts its canonical repressive function. 
We also report that RING1B co-occupy together with EWSR1-FLI1 
many intergenic and intronic regions decorated with H3K27ac. A 
strong enrichment in GGAA repeats has been described in regulatory 
elements where EWSR1-FLI1 binds producing active enhancers 
(10). The presence of GGAA repeats, as well as the H3K27ac associ-
ation, indicates that cobinding of RING1B and EWSR1-FLI1 occurs 
in active enhancers. BMI1 or EZH2 was not found at these en-
hancer regions, suggesting a Polycomb-independent function for 
RING1B. Enhancers are key regulatory regions implicated in cell 
fate determination. Here, we unveiled that an aberrant transcrip-
tion factor such as EWSR1-FLI1 relies on RING1B to activate en-
hancers, causing an altered gene expression profile, which favor 
cell transformation.
Transcription regulation and EWSR1-FLI1 recruitment by RING1B
In accordance with RNA-seq data from melanoma and breast cancer, 
where a positive association of RING1B with transcription activa-
tion has been reported (14, 27), we observed in EwS cells a higher 
number of genes activated than repressed by RING1B. We found 
NKX2-2, SOX2, and IGF1 being direct targets down-regulated both 
in vivo and in vitro upon RING1B knockdown. In EwS, NKX2-2 
and SOX2 are key players in tumorigenesis (21, 23), suggesting that 
modulation of their expression in vivo upon RING1B knockdown 
might contribute to decreased tumor volume and better survival, 
supporting an oncogenic role for RING1B.
Recent studies in hpMSCs have demonstrated that, before onco-
gene recruitment, H3K27me3 is enriched at regions where EWSR1-
FLI1 could bind (39). In agreement with these data, we further 
demonstrate that upon EWSR1-FLI1 expression, those same regions 
loose H3K27me3 marks while becoming transcribed. Moreover, we 
report that enrichment in Polycomb repressed chromatin states is 
specific for H1-, adipose- and BM-derived MSCs, reinforcing hMSC as 
the putative cell of origin, which has already been described by other 
groups (4, 21). The existence of H3K27me3 repressed regions deco-
rated only with PRC1 complex has already been described during 
differentiation of neural precursor cells, where RING1B and PCGF2 
are retained while the PRC2 subunit Suz12 is not (40). In melanoma, 
CCND2 is marked with H3K27me3 before RING1B activation by 
phosphorylation (14). We have observed that GGAA repeats are 
differentially enriched in the binding motif analysis when RING1B 
is associated to chromatin with EWSR1-FLI1. In this scenario, given 
the interaction observed for RING1B and EWSR1-FLI1, it is tempt-
ing to speculate that RING1B targets EWSR1-FLI1 to specific sites. 
In line with this hypothesis, the reduced recruitment of EWSR1-FLI1 
to chromatin (including enhancer regions, such as NKX2-2, SOX2, 
and IGF1) upon RING1B knockdown underlines the importance of 
RING1B in the initials steps of EwS tumorigenesis. Overall, our data 
suggest that RING1B is required for the recruitment of EWSR1-FLI1 
to multimeric GGAA repeats (Fig. 6F).
Beyond EWSR1-FLI1
We have demonstrated that RING1B is an essential partner of 
EWSR1-FLI1 triggering chromatin remodeling. Recent studies 
demonstrated the requirement of SWI/SNF, WDR5, and p300 acetyl-
transferase for EWSR1-FLI1–induced transcription. Similarly, in 
synovial sarcoma, the SS18-SSX oncogenic fusion protein and the 
SWI/SNF complex colocalize at KDM2B-repressed target genes 
together with the noncanonical PRC1.1 complex to produce tran-
scriptional active regions (41). Along the same lines, in leukemia, 
noncanonical PRC1.1 also targets active genes independently of 
H3K27me3 (42). Further mechanistic insights are needed to elucidate 
the contribution of PRC1.1 repressive complex in EwS, where 
somatic mutations in BCOR have been reported (1). The nonca-
nonical PRC1.1 complex contains a DNA binding ZnF-CXXC 
domain able to target chromatin via KDM2B (43). ZNF/repeats 
chromatin state was statistically enriched in five of the six EwS 
cell lines analyzed.
Recently, different cell models have shown that the E3 ubiquitin 
ligase activity of RING1B is inactivated by phosphorylation (15, 36). 
Our results showing the recruitment of AURKB to enhancers are 
compatible with a model in which RING1B is unable to repress the 
newly formed ES enhancers, which were previously Polycomb- 
repressed regions. Once the oncogene binds to chromatin, RING1B 
would cooperate to induce transcription activation if its ubiquitin ligase 
activity is inhibited by phosphorylation (either directly or indirectly) 
(Fig. 6F). More studies are needed to clarify how oncogenic fusion 
proteins act as binding scaffolds to recruit a specific set of interactors to 
generate previously unknown functional units (such as neo-enhancers).
Targeting RING1B with AZD1152
Inhibition of super-enhancers activity with BET inhibitors has 
emerged as a successful preclinical strategy in the fight against dif-
ferent pediatric cancers such as EwS, neuroblastoma, and rhabdo-
myosarcoma (44–46). Inhibition of AURKB with AZD1152 increases 
H2Aub and decreases expression of key oncogene targets, thus sug-
gesting that RING1B is essential for enhancer deregulation by 
EWSR1-FLI1. Nevertheless, as RING1B account for catalytic and 
noncatalytic dependencies (14), further investigation should address 
its clinical therapeutic implications. In agreement with our data, 
combined inhibition of AURKA and AURKB, as well as synergistic 
activity of AURKB with focal adhesion kinase inhibitors, has been 
described effective in EwS preclinical studies, although AURKB ef-
ficiency as single agent has not been proved (47, 48). In EwS cells, 
AZD1152 could affect the levels of RING1B, and this likely reverberates 
on the regulation of the oncogene’s promoter since RING1B occupies 
the EWSR1 promoter (fig. S6, E and G).
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In summary, we demonstrate the oncogenic dependency to high 
levels of RING1B in EwS. The data support a model in which 
RING1B plays a pivotal role for EWSR1-FLI1 recruitment to the 
multimeric DNA repeats. This, in turn, allows for transcriptional 
activation that defines the characteristic transcriptome of EwS. Given 
the role of RING1B in the activation of super-enhancers, which are 
critical elements for cell fate determination, we propose that the 
EwS cell of origin is predefined by high levels of RING1B.
MATERIALS AND METHODS
Cell culture and cell viability assays
The Ewing’s sarcoma cell lines A673, SK-ES1, and A4573, which 
carry the EWSR1-FLI1 translocation types I, II, and III, respectively, 
and the HEK293 cell line from human embryonic kidney infected 
with AgT from SV40 (293T), were cultured in RPMI 1640 media 
(Gibco) and supplemented with 10% fetal bovine serum, l-glutamine, 
and penicillin/streptomycin. Cells were cultured at 37°C with 5% CO2. 
The A673 and SK-ES1 cell lines harboring shCTRL and shRING1B 
with seq#1 and seq#2 as well as A673 cell line with doxycycline 
inducible knockdown of EWSR1-FLI1 were previously described 
(11, 18). hpMSCs were isolated following published protocols (21). 
Ectopic expression of EWSR1-FLI1 3xFLAG C terminus in HeLa cells 
was induced with doxycycline (0.5 g/ml) (34).
All experiments performed with AZD1152 were incubated 72 hours, 
with the exception of RNA expression assays that were incubated 
24 hours. For IC50 calculations, A673, SK-ES1, A4573, and 293T cell 
lines were seeded at 2000 cells per well in 96-well culture plates. 
AZD1152 and PRT4165 (Sigma-Aldrich) was added to complete 
growth medium; after 72 hours, cells were subjected to the ATPlite 
assay (PerkinElmer), and measurements were performed using a 
Tecan plate reader. Inhibitory concentrations were calculated using 
OriginPro 9.0 software.
Plasmids and small interfering RNA transfection
EWSR1-FLI1 type 2 was amplified from a pSG5 vector with primers 
containing Bgl II and Hind III sequences (forward, 5′-ggaggaag-
gAGATCTAATGGCGTCCACGG-3′; reverse, 5′-aagAAGCTTGTAG-
TAGCTGCCTAA-3′). The PCR product was purified using an 
Illustra GFX PCR DNA and Gel Band Purification kit (GE Healthcare 
Life Sciences). The product of the amplification was subcloned into 
the TOPO TA Cloning Kit for Sequencing following the manufac-
turer’s instructions. TOPO-EWSR1-FLI1 plasmid and the acceptor 
vector pEGFP-N1 were double digested with Bgl II and Hind III at 
37°C. The resulting EWSR1-FLI1 band was ligated into pEGFP-N1, 
and ligation product was then transformed into JM109 cells.
Target sequences for siRNA are described in table S6. Trans-
fection of small duplexes (Sigma-Aldrich) was performed with Li-
pofectamine RNAiMAX and Optimem (Invitrogen), using 30 pmol 
when cells were 80% confluent; samples were collected after a 72-hour 
incubation. Transient transfections of GFP constructs or empty vec-
tor were done using FuGENE XP (Roche) with 1 to 2 g of plasmid 
when cells were 60% confluent; samples were collected after 
48 hours. Both reagents were used according to the manufacturer’s 
recommendations.
Lentivirus infection
Empty pLIV and EWSR1-FLI1pLIV–expressing lentiviruses were 
provided by N. Riggi (University Institute of Pathology Lausanne, 
Switzerland). Lentiviruses were produced in Lenti-X 293T packaging 
cells (Takara, Cultek) at a low passage number. For each plate, 7 g 
of the lentiviral plasmid, 5 g of the envelope plasmid (VSV-G), and 
6 g of the packaging plasmid (PAX8) were prepared and introduced 
by calcium phosphate transfection, according to standard protocols. 
The supernatant containing lentiviruses was collected 48 hours after 
transfection. The HUVEC cell line was seeded at 3000 cells/cm2 
and transduced with 3:1 of the lentiviral supernatant with fresh 
media containing Polybrene (Sigma-Aldrich) at 6 g/ml. Cells 
were selected with fresh growth media containing puromycin 
(0.3 g/ml) for 72 hours. A control dish without the transduction 
media was also selected with puromycin, to control for killing of 
nontransduced cells.
Cell extract preparation, immunoprecipitation,  
and Western blotting
Histone extracts of cultured cells were isolated using the EpiQuick 
Histone Extraction kit (Epigentek) following the manufacturer’s in-
structions. Total cell extracts were prepared in IPH buffer [50 mM 
tris-HCl (pH 8), 150 mM NaCl, 5 mM EDTA, and 0.5% NP-40] with 
EDTA-free protease inhibitor cocktail (Roche). For protein, fractionation 
standard protocols were used. Histone or total protein extracts were 
quantified by Bradford assay. Immunoprecipitation was performed 
with total cellular extracts incubated at 4°C overnight with primary 
antibody. After incubation of immunoprecipitated samples on protein 
A/G and agarose beads (Santa Cruz Biotech), 30 to 50 g of whole 
protein extracts or 5 g of histones was resolved by polyacrylamide gel 
electrophoresis. Western blotting was performed using standard pro-
tocols. Incubation with primary antibodies was done at 4°C overnight 
and LI-COR secondary antibodies that are detectable by near- infrared 
fluorescence were used for detection (table S6). Blots were scanned 
with an Odyssey CLx Infrared Imaging System at medium intensities.
Cell cycle analysis and Annexin V staining
Treated cells were fixed in 70% ethanol, stained with 25 l of propidium 
iodide (PI) (1 mg/ml), and 25 l of ribonuclease (RNase) (10 mg/ml), 
and incubated 30 min at 37°C. For Annexin V binding, the Alexa 
Fluor 488 fluorophore kit (Invitrogen) was used for apoptotic cell 
detection. After culture and treatment, cells were resuspended in 
annexin binding buffer with 5 l of Alexa Fluor 488 Annexin V and 
1 l of PI working solution (100 g/ml). After 15 min, samples were 
run in Gallios multicolor flow cytometer (Beckman Coulter) set up 
with the 3-lasers, 10 colors standard configuration. Histograms and 
cytograms were further analyzed with FlowJo 10.2.
RNA extraction and RT-qPCR
Total RNA was isolated and purified from collected cells using the 
RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. 
After quantification using the NanoDrop software (Thermo Fisher 
Scientific), RT was performed. A 1-g aliquot of each RNA sample 
was converted to cDNA in a reaction catalyzed by a retrotranscriptase 
enzyme (M-MLV Reverse Transcriptase Promega). Random primers 
and RNase inhibitor (RNasin Plus RNase Inhibitor, Promega) were 
also added to the reaction. cDNA obtained was analyzed by qPCR 
using SYBR Green PCR Master Mix (ABI). cDNA was amplified with 
specific oligonucleotides (table S6). Each cDNA sample was run in 
triplicate, and its levels were analyzed using the 7500 Fast PCR instru-
ment (Applied Biosystems). To compare between different condi-
tions studied, relative quantification of each target was normalized 
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to a housekeeping gene. Last, data were analyzed using the compar-
ative 2-ct method.
Microarray gene expression and RNA-seq
Gene expression microarrays were performed at the Microarray 
Analysis Service, Hospital del Mar Medical Research Institute (IMIM, 
Barcelona). RNA samples were amplified, labeled according to a 
GeneChip WT PLUS Reagent kit, and hybridized to Human Gene 
2.0 ST (Affymetrix) in a GeneChip Hybridization Oven 640. Washing 
and scanning were performed using the Expression Wash, Stain, 
and Scan Kit and the GeneChip System of Affymetrix (GeneChip 
Fluidics Station 450 and GeneChip Scanner 3000 7G). After quality 
control, raw data were background corrected, quantile-normalized, 
and summarized to a gene level using the robust multichip average; 
a total of 48,144 transcript clusters, excluding controls, were obtained, 
which roughly corresponds to genes and other RNAs, such as 
long intergenic noncoding RNAs and microRNAs. NetAffx 36 
annotations, based on the human genome 19, were used to summarize 
data into transcript clusters and to annotate analyzed data. Linear 
Models for Microarray (limma), a moderated t statistics model, was 
used for detecting differentially expressed genes between the condi-
tions. All data analyses were performed in R (version 3.4.3) with R/
Bioconductor packages aroma.affymetrix, Biobase, affy, limma, gene-
filter, ggplots, and Vennerable. Genes with a P less than 0.05 were 
selected as significant.
Raw sequencing reads in the fastq files were mapped with STAR 
version 2.6.a (49). GENCODE release 29, based on the GRCh38 refer-
ence genome, and the corresponding GTF file were used. The table of 
counts was obtained with featureCounts function in the package subread, 
version 1.6.4. The differential gene expression analysis (DEG) was 
assessed with voom+limma in the limma package version 3.40.2 and 
using R version 3.6.0. Raw library size differences between samples 
were treated with the weighted “trimmed mean method” imple-
mented in the edgeR package. Clustering method used is Ward.D2 
with correlation distances and principal components analysis. For 
the differential expression analysis, read counts were converted to 
log2 counts per million, and the mean-variance relationship was 
modeled with precision weights using voom approach in limma 
package. Raw data are accessible at the NCBI Gene Expression 
Omnibus (GEO) accession code GSE131286.
Functional analysis of expression data
Intersection of DEG for A673 shRING1B knockdown with those 
for A673 shEWSR1-FLI1 with accession number GSE61953 (10) 
was obtained by calculating a delta-score as described by the au-
thors. Absolute FC > 1.25 and 1.5 for RING1B and EWSR1-FLI1 
datasets were selected, respectively. Overlaps for positive and 
negative gene sets were obtained using Vennerable R package 
and BioVenn. Functional analysis of the intersection between 
RING1B and EWSR1-FLI1 gene lists was performed in Enrichr. 
Normalized enrichment scores on A673 and SK-ES1 shRING1B 
versus shCTRL were obtained with GSEA using the Hallmark 
gene set collection. GSEA was used to analyze enrichment on the 
list of 983 down-regulated TSG in tumor samples versus normal 
tissue from TSGene database (50) (https://bioinfo.uth.edu/
TSGene/). Analysis of expression levels for AURKB, CSNK2A1, 
and MAP2K1 were performed using information from GEO2R 
GSE7007 for the probes 209464_at, 212075_s_at, and 202670_at, 
respectively.
Immunohistochemistry
Immunohistochemical analyses were performed following standard 
techniques. The antibodies used are given in table S6. Tumors 
were fixed in formalin and embedded in paraffin for subsequent 
processing. Consecutive, sections were deparaffinized, rehydrated, 
and heated with Epitope Retrieval Solution (pH 6.0) (Novocastra 
Laboratories). Reactions were developed with Novolink Polymer 
Detection System (Novocastra Laboratories). Immunoreactivity was 
visualized by diaminobenzidine, and nuclei were counterstained with 
hematoxylin. Tissue was then dehydrated with alcohol, permeated 
with xylene, and mounted with Permount organic mounting solu-
tion (Thermo Fisher Scientific). Images were evaluated by a pathol-
ogist to select regions of interest and analyzed with the Dotslide 
Microscope and Olympia Software (Olympus). Similar regions of 
every sample were selected from every section.
Chromatin immunoprecipitation followed by quantitative 
polymerase chain reaction
Cells were treated with 1% formaldehyde at room temperature for 
10 min, and the cross-linking reaction was stop by adding 500 l 
glycine (1.25 M). Cells were resuspended in lysis buffer [0.1% SDS, 
0.15 M NaCl, 1% Triton X-100, 1 mM EDTA, 20 mM tris (pH 8), 
and protease inhibitors (1 mg/ml)] and sonicated with Bioruptor 
Pico (Diagenode) for 10 cycles until chromatin was sheared to an 
average fragment length of 200 bp. After centrifugation, a small 
fraction of eluted chromatin was measured with Qubit. Starting with 
30 g of sample, immunoprecipitation for each antibody was per-
formed overnight (table S6); 50 l of Dynabeads Protein A (Invitrogen) 
was then added and incubated for 2 hours at 4°C under rotation. 
Immunoprecipitates were washed once with TSE I [0.1% SDS, 1% 
Triton X-100, 2 mM EDTA, 20 mM tris-HCl (pH 8), and 150 mM 
NaCl], TSE II [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM 
tris-HCl (pH 8), and 500 mM NaCl], and TSE III [0.25 M LiCl, 1% 
Nonidet P-40, 1% deoxycholate, 1 mM EDTA, and 10 mM tris-HCl 
(pH 8)] and then twice with tris-EDTA buffer. Washed pellets were 
eluted with 120 l of a solution of 1% SDS and 0.1 M NaHCO3. Eluted 
pellets were decross-linked for 5 hours at 65°C and purified on 50 l of 
tris-EDTA buffer with the QIAquick PCR Purification Kit (Qiagen). 
Differences in the DNA content at each binding region (sequences 
in table S6) from every immunoprecipitation assay were determined 
by real-time PCR using the ABI 7700 sequence detection system 
and SYBR Green master mix protocol (Applied Biosystems). Each 
immunoprecipitation was done in triplicate, and PCR assays were 
performed using fixed amounts of input and immunoprecipitated 
DNA. For every amplicon, standard curves to calculate efficiency 
and melting curves to confirm single amplicons were obtained. The 
reported data represent real-time PCR values normalized to input 
DNA and are expressed as percentage (%) of bound/input signal.
ChIP-seq and bioinformatic analysis
Libraries were prepared using the NEBNext Ultra DNA Library Prep 
from Illumina according to the manufacturer’s protocol. Briefly, 
5 ng of input and ChIP-enriched DNA were subjected to end repair 
and addition of “A” bases to 3′ ends, ligation of adapters, and USER 
excision. All purification steps were performed using AgenCourt 
AMPure XP beads (Qiagen). Library amplification was performed 
by PCR using NEBNext Multiplex Oligos from Illumina. Final libraries 
were analyzed using Agilent high sensitivity chip to estimate the 
quantity and to check size distribution and then were quantified by 
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qPCR using the KAPA Library Quantification Kit (KapaBiosystems) 
before amplification with Illumina’s cBot. Libraries were loaded onto 
the flow cell sequencer 1 × 50 on Illumina’s HiSeq 2500.
ChIP-seq samples were mapped against the hg19 human genome 
assembly using BowTie with the option –m 1 to discard those reads 
that could not be uniquely mapped to just one region. A second replicate 
of RING1B and H2Aub was sequenced to evaluate the statistical sig-
nificance of the results. Model-based analysis of ChIP-seq (MACS) was 
run individually on each replicate with the default parameters but 
with the shift size adjusted to 100 bp to perform the peak calling 
against the corresponding control sample (51). DiffBind was initially 
run over the peaks reported by MACS for each pair of replicates of 
the same experiment to generate a consensus set of peaks (28). Next, 
DiffBind was run again over each pair of replicates of the same ex-
periment, samples and inputs, to find the peaks from the consensus 
set that were significantly enriched in both replicates in comparison 
to the corresponding controls (categories, DBA_CONDITION; 
block, DBA_REPLICATE; and method, DBA_DESEQ2_BLOCK). 
DiffBind RING1B peaks with P < 0.05 and H2Aub peaks with P < 
0.05 and false discovery rate < 0.00001 were selected for further 
analysis. The genome distribution of each set of peaks was calculated 
by counting the number of peaks fitted on each class of region ac-
cording to RefSeq annotations. Promoter is the region between 
2.5 kb upstream and 2.5 kb downstream of the TSS. Genic regions 
correspond to the rest of the gene (the part that is not classified as 
promoter), and the rest of the genome is considered to be intergenic. 
Peaks that overlapped with more than one genomic feature were 
proportionally counted the same number of times. Each set of target 
genes was retrieved by matching the ChIP-seq peaks in the region 
2.5 kb upstream of the TSS until the end of the transcripts as anno-
tated in RefSeq. Reports of functional enrichments of GO categories 
were generated using the EnrichR tool. Aggregated plots showing 
the average distribution of ChIP-seq reads around the summit of 
each peak were generated by counting the number of reads for each 
region and then averaging the values for the total number of mapped 
reads of each sample and the total number of peaks in the particular 
gene set. To perform the comparison between two sets of peaks, a 
minimum overlap of one nucleotide was necessary to consider one 
match. The heatmap displaying the density of ChIP-seq reads 5 kb 
around the summit of each peak set were generated by counting the 
number of reads in this region for each individual peak and normal-
izing this value with the total number of mapped reads of the sample. 
Peaks on each ChIP heatmap were ranked by the logarithm of the 
average number of reads in the same genomic region. On the other 
hand, we separated the single peaks of RING1B into distal and TSS 
(±5 kb around one RefSeq gene) to generate the heatmap of ChIP-seq 
signal strength of RING1B, EWSR1-FLI1, H3K27me3, H2Aub, and 
H3K27ac over the two classes of RING1B peaks detected above 
(distal and TSS). To build our collection of enhancers and promoters, 
we reanalyzed published ChIP-seq samples of H3K4me1, H3K27ac, 
H3K27me3, and H3K4me3 in A673 cells (10). H3K27ac and H3K27me3 
peaks were used to discriminate between active or repressed regula-
tory regions. Promoters were defined as ChIP peaks of H3K27 found 
up to 2.5 kb from the TSS of one gene and enhancers on intergenic 
areas outside promoters or within gene introns. H3K4me3 was re-
quired to be present in promoters but absent in enhancers. We de-
fined four classes of regulatory elements: active enhancers (H3K27ac), 
active promoters (H3K27ac + H3K4me3), poised enhancers 
(H3K27me3), and bivalent promoters (H3K27me3 + H3K4me3). 
The MEME-ChIP tool was used to perform motif-finding analysis 
of the sequences bound by each factor. The UCSC genome browser 
was used to generate the screenshots of each group of experiments 
along the manuscript (52). Raw data, genome-wide profiles, and 
peaks of each ChIP-seq experiment are accessible at the NCBI GEO 
accession code GSE131286.
Chromatin state analysis of EWSR1-FLI1 binding regions
We have determined the composition of 3945 EWSR1-FLI1 biding 
sites in terms of 15 chromatin states from the segmentations gener-
ated by Epigenome Roadmap Consortium (GEO code: GSE61953) 
for six different cell types: HUVECs (E122), H1 (E003) and H9 ES 
cells (E008), H1-derived mesenchymal stem cells (E006), BM-derived 
MSCs (E026), and adipose-derived MSC (E025) (26). The statistical 
significance of the relative frequency of each stage at every cell type 
was assessed in comparison to the same value measured along 
the whole genome, using the Fisher’s exact test. The R package 
GenomicRanges from Bioconductor was used for calculations of 
compositions. Next, to generate the final heatmap, we have grouped 
certain states for semantic similarity (active TSS category includes 
active and flanking active TSS states; transcription includes flank-
ing, strong, and weak states; enhancers account for both genic and 
intergenic; bivalent TSS include also flanking bivalent promoters 
and PcG repressed include both repressed and weak repressed). 
Thus, the relative frequencies of the new eight states were recalcu-
lated, while quiescent state was discarded from the analysis. Last, 
the enrichment percentage at a particular stage was calculated as the 
difference between the relative frequency at the EWSR1-FLI1 ChIP-seq 
sites minus the relative frequency at the whole genome normalized 
by the relative frequency at the whole genome again.
Mouse xenograft models
In vivo studies were performed after the approval of the Institutional 
Animal Research Ethics Committee. Athymic nude mice (Envigo) 
were injected subcutaneously with 4 × 106 cells for shCTRL#seq1 
and shRING1B#seq1 and 2 × 106 for seq#2. shCTRL cells were re-
suspended in 200 l of Matrigel (Becton Dickinson) with phosphate- 
buffered saline and injected into both flanks (5 mice n = 10 for seq#1 
and 6 mice, n = 12 for seq#2). The same procedure was performed 
for the SK-ES1 shRING1B cell line. Tumor growth was monitored 
three times a week by measuring tumor volume with a digital caliper. 
Mice were euthanized when tumors reached a size of 2.5 cm in any 
dimension. Survival curves were calculated using the Kaplan-Meier 
method and were compared with a log-rank test. At the end of the 
experiment, tumors were excised; half of each specimen was frozen 
in liquid nitrogen for RNA extraction, and the other was fixed in 
10% formalin for immunohistochemistry experiments.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/43/eaba3058/DC1
View/request a protocol for this paper from Bio-protocol.
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